Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Apple and medical device company Masimo are currently embroiled in multiple legal battles, headlined by the ongoing fight over the Apple Watch’s blood oxygen sensor. In a separate case ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

4 analysts have expressed a variety of opinions on Masimo MASI over the past quarter ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Reports Q3 revenue $504.6M, consensus $502.67M. Michelle Brennan, Interim Chief Executive Officer of Masimo (MASI), said, “We are pleased ...

Consensus $3.88. Cuts FY24 revenue view to $2.075B-$2.105B form $2.085B-$2.135B, consensus $2.1B. Published first on TheFly – the ...

Good afternoon, ladies and gentlemen, and welcome to Masimo's third-quarter 2024 earnings ... a discussion of the potential separation of our consumer business and a preliminary estimate of ...

But if Masimo decides to no longer pursue a spinoff of the consumer segment into a publicly traded company, it expects to treat the business as a discontinued operation, Young explained ...